Search the site

News & Events

How much is the right amount of therapy?

In this blog, CliniKids Director Professor Andrew Whitehouse and Research Development Manager Sarah Pillar explore one of the most common questions when it comes to support for autistic children - how much is the right amount of therapy?

Primary School Workshop Incursions

Everything you need to know to book a The Kids 'Meet a Researcher' incursion.

Kids Rehab Research WA

Kids Rehab WA is an integrated team of clinicians and researchers who deliver and research therapies for children with acquired or congenital neurological impairments, leading to improved outcomes for children and their families.

Research

DETECT Schools

The DETECT-Schools Study was launched in May 2020 as a partnership between the WA Government Departments of Education and Health with The Kids Research Institute Australia.

Research outputs

Find out about the research outputs for the Development Pathways Project, and see the published research outcomes.

Research

Intellectual Disability

About 2 per cent of children are estimated to have an intellectual disability. The cause of the condition is unknown in at least 50 per cent of cases.

Research

Rett Syndrome

A severe neurodevelopmental disorder mostly affecting girls.

Research

The Early Start Screen Smart Program

Supporting families to create healthy screen time habits

Research

Improving sport opportunities, participation, and experiences for children in out-of-home care: A mixed-methods study

Participation in sport is associated with a range of physical, psychological, and social benefits. However, children in out-of-home care face complex barriers to sport participation, with lower participation rates than children in other household arrangements.

Research

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.